Yesterday, March 3, 2016, 128 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $7.31 to $24,274,480.00.

Highlighted Stocks Traded by Insiders:

Everest Re Group (RE) - FREE Research Report

Singer Roger M., who is Director at Everest Re Group, sold 1,000 shares at $189.97 on March 3, 2016. Following this transaction, the Director owned 10,332 shares meaning that the stake was reduced by 8.82% with the 1,000-share transaction.

The shares most recently traded at $190.41, up $0.44, or 0.23% since the insider transaction. Historical insider transactions for Everest Re Group go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 2,687
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 2,687
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 2,887

The average volume for Everest Re Group has been 317,200 shares per day over the past 30 days. Everest Re Group has a market cap of $8.2 billion and is part of the financial sector and insurance industry. Shares are up 4.86% year-to-date as of the close of trading on Thursday.

Everest Re Group, Ltd., through its subsidiaries, provides reinsurance and insurance products. The company operates through U.S. Reinsurance, International, Bermuda, Insurance, and Mt. Logan Re segments. The U.S. The stock currently has a dividend yield of 2.4%. The company has a P/E ratio of 8.7. Currently, there are 2 analysts who rate Everest Re Group a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RE - FREE

TheStreet Quant Ratings

rates Everest Re Group as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Everest Re Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ensign Group (ENSG) - FREE Research Report

Hubenette Antoinette T., who is Director at Ensign Group, sold 6,668 shares at $20.53 on March 3, 2016. Following this transaction, the Director owned 18,626 shares meaning that the stake was reduced by 26.36% with the 6,668-share transaction.

The shares most recently traded at $21.96, up $1.43, or 6.51% since the insider transaction. Historical insider transactions for Ensign Group go as follows:

  • 4-Week # shares sold: 359
  • 12-Week # shares sold: 15,881
  • 24-Week # shares sold: 16,992

The average volume for Ensign Group has been 305,400 shares per day over the past 30 days. Ensign Group has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are down 4.86% year-to-date as of the close of trading on Thursday.

The Ensign Group, Inc. provides health care services in the post-acute care continuum, urgent care center, and mobile ancillary businesses in the United States. It operates through two segments, Transitional, Skilled and Assisted Living Services; and Home Health and Hospice Services. The stock currently has a dividend yield of 0.77%. The company has a P/E ratio of 19.6. Currently, there are 5 analysts who rate Ensign Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENSG - FREE

TheStreet Quant Ratings

rates Ensign Group as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and compelling growth in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Ensign Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eplus (PLUS) - FREE Research Report

Callies John E, who is Director at Eplus, sold 1,000 shares at $75.53 on March 3, 2016. Following this transaction, the Director owned 6,557 shares meaning that the stake was reduced by 13.23% with the 1,000-share transaction.

The shares most recently traded at $76.40, up $0.87, or 1.14% since the insider transaction. Historical insider transactions for Eplus go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 8,500
  • 24-Week # shares sold: 53,763

The average volume for Eplus has been 111,900 shares per day over the past 30 days. Eplus has a market cap of $562.8 million and is part of the technology sector and computer software & services industry. Shares are down 17.56% year-to-date as of the close of trading on Thursday.

ePlus inc., through its subsidiaries, provides information technology (IT) products and services, flexible leasing and financing solutions, and enterprise supply management in the United States. It operates through two segments, Technology and Financing. The company has a P/E ratio of 12.6. Currently, there is 1 analyst who rates Eplus a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on PLUS - FREE

TheStreet Quant Ratings

rates Eplus as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Eplus Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.